Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meike de Wit

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
European Journal of Cancer (Oxford, England : 1990)|December 20, 2020
Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancerSjoerd H den Uil, Meike de Wit, Robbert J C Slebos, et al.
The Journal of Pathology|December 1, 2019
Proteins in stool as biomarkers for non-invasive detection of colorectal adenomas with high risk of progressionMalgorzata A Komor, Linda Jw Bosch, Veerle Mh Coupé, et al.
Cancer Prevention Research (Philadelphia, Pa.)|April 25, 2018
Evaluation of Cancer-Associated DNA Copy Number Events in Colorectal (Advanced) AdenomasBeatriz Carvalho, Begoña Diosdado, Jochim S Terhaar Sive Droste, et al.
Cancer Research Communications|November 3, 2023
Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case-Control StudyHenriette C Jodal, Eddymurphy U Akwiwu, Margriet Lemmens, et al.
Annals of Internal Medicine|July 19, 2021
Clinical Validation of a Multitarget Fecal Immunochemical Test for Colorectal Cancer Screening : A Diagnostic Test Accuracy StudyWillemijn de Klaver, Pieter H A Wisse, Francine van Wifferen, et al.
The Lancet. Oncology|February 12, 2024
The multitarget faecal immunochemical test for improving stool-based colorectal cancer screening programmes: a Dutch population-based, paired-design, intervention studyPieter H A Wisse, Willemijn de Klaver, Francine van Wifferen, et al.
Oncotarget|July 15, 2015
MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patientsKristiaan Lenos, Jeroen A C M Goos, Ilona M Vuist, et al.
International Journal of Cancer|August 15, 2019
Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progressionMalgorzata A Komor, Meike de Wit, Jose van den Berg, et al.
The American Journal of Surgical Pathology|June 17, 2011
SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomasKristina Magnusson, Meike de Wit, Donal J Brennan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2012
Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal cancerRemond J A Fijneman, Meike de Wit, Maral Pourghiasian, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
European Journal of Cancer (Oxford, England : 1990)|December 20, 2020
Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancerSjoerd H den Uil, Meike de Wit, Robbert J C Slebos, et al.
The Journal of Pathology|December 1, 2019
Proteins in stool as biomarkers for non-invasive detection of colorectal adenomas with high risk of progressionMalgorzata A Komor, Linda Jw Bosch, Veerle Mh Coupé, et al.
Cancer Prevention Research (Philadelphia, Pa.)|April 25, 2018
Evaluation of Cancer-Associated DNA Copy Number Events in Colorectal (Advanced) AdenomasBeatriz Carvalho, Begoña Diosdado, Jochim S Terhaar Sive Droste, et al.
Cancer Research Communications|November 3, 2023
Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case-Control StudyHenriette C Jodal, Eddymurphy U Akwiwu, Margriet Lemmens, et al.
Annals of Internal Medicine|July 19, 2021
Clinical Validation of a Multitarget Fecal Immunochemical Test for Colorectal Cancer Screening : A Diagnostic Test Accuracy StudyWillemijn de Klaver, Pieter H A Wisse, Francine van Wifferen, et al.
The Lancet. Oncology|February 12, 2024
The multitarget faecal immunochemical test for improving stool-based colorectal cancer screening programmes: a Dutch population-based, paired-design, intervention studyPieter H A Wisse, Willemijn de Klaver, Francine van Wifferen, et al.
Oncotarget|July 15, 2015
MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patientsKristiaan Lenos, Jeroen A C M Goos, Ilona M Vuist, et al.
International Journal of Cancer|August 15, 2019
Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progressionMalgorzata A Komor, Meike de Wit, Jose van den Berg, et al.
The American Journal of Surgical Pathology|June 17, 2011
SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomasKristina Magnusson, Meike de Wit, Donal J Brennan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2012
Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal cancerRemond J A Fijneman, Meike de Wit, Maral Pourghiasian, et al.
Pageof 4